Latest News

China Medical System’s Innovative Oral Drug for Vitiligo, JAK1 Inhibitor Povorcitinib Enrolls First Patient in China Phase III Clinical Trial
2026-11-19

China Medical System’s Innovative Oral Drug for Vitiligo, JAK1 Inhibitor Povorcitinib Enrolls First Patient in China Phase III Clinical Trial

The first patient has been enrolled in the Phase IIIclinical trial of povorcitinib for vitiligo in China, with approximately 174 patients planned for enrollment. The Product has previously been included in the list of Breakthrough Therapeutic Drugs by China’s NMPA. This certification has the potential to accelerate its development and review process. The Product is a selective oral small-molecule JAK1 inhibitor, and its overseas Phase IIIclinical studies for vitiligo have met the primary endpoints. This clinical progress lays an important foundation for further evaluating the efficacy and safety of the Product in Chinese patients with vitiligo. If approved in China, the Product, together with the commercialized innovative drug ruxolitinib phosphate cream, has the potential to provide vitiligo patients with comprehensive and diversified treatment options, from precise topical intervention to systemic treatment. It would also further strengthen Dermavon’s competitive advantages in skin health.   China Medical System Holdings Limited (“CMS” or […]

Learn More
CMS Honored with the 2026 Stock Star Capital Power “Outstanding Listed Company Award”
2026-11-10

CMS Honored with the 2026 Stock Star Capital Power “Outstanding Listed Company Award”

On November 6, 2026, at the 14th “Capital Power” annual brand event hosted by Stock Star, CMS was honored with the “Outstanding Listed Company Award” in recognition of its outstanding performance in differentiated innovation strategy, solid operating results, and corporate governance. Since its launch in 2012, Stock Star’s “Capital Power” annual brand event has been held for 14 consecutive editions, dedicated to identifying outstanding companies in the capital market and providing evaluation and benchmarks for the development of the financial industry and listed companies. The “Outstanding Listed Company Award” focuses on assessing a company’s products and technologies competitiveness, value creation capability, operating resilience, investment in innovative R&D, and corporate governance standards. This award underscores the capital market’s full recognition of CMS’s overall strength, innovation achievements, and sound governance. CMS has been deeply engaged in the pharmaceutical industry for more than 30 years, focusing on the identification, building, and full lifecycle management of differentiated […]

Learn More
CMS: Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment
2026-11-04

CMS: Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment

Ruxolitinib phosphate cream is the first and only topical prescription drug in Singapore that directly targets the pathophysiological mechanism of vitiligo. It is also the first drug specifically for repigmentation in non-segmental vitiligo, filling a decades-long void in the field and offering new hope for patients.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Rxilient Medical received approval from the Health Sciences Authority of Singapore (HSA) on 3 November 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product” or “Lumirix®”) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. It is the first and only topical prescription drug in Singapore that directly targets the pathophysiological mechanism of vitiligo[1], meeting a long-standing unmet clinical need. This approval fills a gap in the field of vitiligo treatment in Singapore. In addition to Singapore, Rxilient Medical has already launched sales of […]

Learn More

The news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.

All News